EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Augmenting and Assaying Nav1.1 Protein Quantity for Dravet Syndrome Therapy

Aiswarya Saravanan iD, Jordan Safran, Anna Loughman, Grace Lin, Shivanshi Vaid, Dana Allababidi, Peter M Tessier, Louis T Dang iD

Annals of Clinical and Translational Neurology · 2026-11 · 13 (11) · 2382-2387

DOI: 10.1002/acn3.70500 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 28.07.2026. Verfasst von Aiswarya Saravanan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: NAV1.1 Voltage-Gated Sodium Channel, Epilepsies, Myoclonic, Induced Pluripotent Stem Cells, Oligonucleotides, Antisense. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University of Michigan Department of Pediatrics, NIA NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dravet Syndrome (DS) is a developmental and epileptic encephalopathy predominantly caused by heterozygous loss‐of‐function variants in SCN1A , which encodes Nav1.1. Conserved upstream open reading frames (uORFs) in SCN1A were validated to regulate translation in reporter assays, demonstrating the therapeutic viability of increasing Nav1.1 from a wild‐type allele. A human induced pluripotent stem cell (iPSC) line with endogenously HiBiT‐tagged Nav1.1 showed dose‐dependent Nav1.1 downregulation with gapmer antisense oligonucleotides (ASOs) and upregulation with splice‐switching ASOs, validating a sensitive quantification platform for endogenous Nav1.1 translation. This iPSC line provides a timely resource for screening translational modulators and validating therapeutic strategies for SCN1A ‐related disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NAV1.1 Voltage-Gated Sodium ChannelEpilepsies, MyoclonicInduced Pluripotent Stem CellsOligonucleotides, AntisenseHumans

Stichwörter der Autor:innen

HiBiTepilepsyhigh throughput screen

Substanzen

NAV1.1 Voltage-Gated Sodium ChannelSCN1A protein, humanOligonucleotides, Antisense

Autor:innen und Institutionen

  • Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Pharmaceutical Sciences, Department of Biomedical Engineering, and Biointerfaces Institute, University of Michigan, Ann Arbor, Michigan, USA.

ORCID-Profile: Aiswarya Saravanan, Louis T Dang

Förderung

  • University of Michigan Department of Pediatrics
  • NIA NIH HHS
  • NINDS NIH HHS
  • Child Neurology Society/Foundation
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Aging

Zitieren

APA

Saravanan, A., Safran, J., Loughman, A., Lin, G., Vaid, S., Allababidi, D., Tessier, P. M., & Dang, L. T. (2026). Augmenting and Assaying Nav1.1 Protein Quantity for Dravet Syndrome Therapy. Annals of Clinical and Translational Neurology, 13(11), 2382-2387. https://doi.org/10.1002/acn3.70500

Vancouver

Saravanan A, Safran J, Loughman A, Lin G, Vaid S, Allababidi D, et al. Augmenting and Assaying Nav1.1 Protein Quantity for Dravet Syndrome Therapy. Annals of Clinical and Translational Neurology. 2026;13(11):2382-2387. doi:10.1002/acn3.70500

BibTeX
@article{Saravanan2026,
  author = {Saravanan, Aiswarya and Safran, Jordan and Loughman, Anna and Lin, Grace and Vaid, Shivanshi and Allababidi, Dana and Tessier, Peter M and Dang, Louis T},
  title = {Augmenting and Assaying Nav1.1 Protein Quantity for Dravet Syndrome Therapy},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  volume = {13},
  number = {11},
  pages = {2382--2387},
  doi = {10.1002/acn3.70500}
}
Kostenlos starten →